We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.625 | 6.25 | 7.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMCOS
Collagen Solutions PLC
20 February 2019
Collagen Solutions Plc
("Collagen Solutions" or the "Company")
Sale of Strategic Investment in Jellagen
Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that it has sold its stake in Jellagen Ltd ("Jellagen") for approximately GBP215,000 in a private transaction.
Jellagen is a private marine biotechnology company founded in 2013 focused on developing collagen biomaterials from jellyfish. Collagen Solutions had held a minority equity position in Jellagen since 2014 and also collaborated on technology development. The transaction to sell Collagen Solutions' shares in Jellagen followed the most recent investment round in Jellagen in which the Company did not participate.
Jamal Rushdy, CEO, commented, "We remain interested in Jellagen's progress as it continues to develop its jellyfish collagen cell culture products for the research markets, and our decision to divest our shares does not preclude future potential opportunities to collaborate with Jellagen. We are pleased with our return on this investment, which we can use to further support our own growth opportunities."
Enquiries:
Collagen Solutions Plc Jamal Rushdy, CEO Via Walbrook Hilary Spence, CFO Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com Anna Dunphy Mob: 07876 741 001 Helen Cresswell Mob: 07841 917 679
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRABRGDDGBBBGCC
(END) Dow Jones Newswires
February 20, 2019 02:01 ET (07:01 GMT)
1 Year Collagen Solutions Chart |
1 Month Collagen Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
